Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7932-7940

  Kudela, Pavol ^a   Janjic, Bratislav ^a   Fourcade, Julien ^a   Castelli, Florence ^b   Andrade, Pedro ^a   Kirkwood, John M ^a   El Hefnawy, Talal ^a   Amicosante, Massimo ^c   Maillere, Bernard ^b   Zarour, Hassane M ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DP ANTIGEN; HLA DR ANTIGEN; T LYMPHOCYTE RECEPTOR; CTAG1B PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CROSS REACTION; DENDRITIC CELL; GENE TRANSFER; HUMAN; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANTIGEN ANTIBODY REACTION; BIOSYNTHESIS; BLOOD; CELL LINE; CELL PROLIFERATION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; HLA-DR ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC;

EID: 38849174832     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7932     Document Type: Article

References (42)

1. Rudolph, M. G., R. L. Stanfield, and I. A. Wilson. 2006. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24: 419-466.
2. Sturniolo, T., E. Bono, J. Ding, L. Raddrizzani, O. Tuereci, U. Sahin, M. Braxenthaler, F. Gallazzi, M. P. Protti, F. Sinigaglia, and J. Hammer. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 17: 555-561.
3. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
4. O'Sullivan, D., J. Sidney, E. Appella, L. Walker, L. Phillips, S. M. Colon, C. Miles, R. W. Chesnut, and A. Sette. 1990. Characterization of the specificity of peptide binding to four DR haplotypes. J. Immunol. 145: 1799-1808.
5. Hammer, J., Z. A. Nagy, and F. Sinigaglia. 1994. Rules governing peptide-class II MHC molecule interactions. Behring Inst. Mitt. 124-132.
6. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160: 3363-3373.
7. Texier, C., S. Pouvelle-Moratille, C. Buhot, F. A. Castelli, C. Pecquet, A. Menez, F. Leynadier, and B. Maillere. 2002. Emerging principles for the design of promiscuous HLA-DR-restricted peptides: an example from the major bee venom allergen. Eur. J. Immunol. 32: 3699-3707.
8. Castelli, F. A., C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J. G. Guillet, A. Menez, B. Georges, and B. Maillere. 2002. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169: 6928-6934.
9. Kobayashi, H., Y. Song, D. S. Hoon, E. Appella, and E. Celis. 2001. Tumor-reactive T helper lymphocytes recognize a promiscuous mage-a3 epitope presented by various major histocompatibility complex class ii alleles. Cancer Res. 61: 4773-4778.
10. + T cells. Cancer Res. 62: 213-218.
11. + T-cell epitopes on the tumor antigen MAGE-3. Blood 101: 1038-1044.
12. + T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174: 1751-1759.
13. + T cells. Cancer Res. 63: 6506-6515.
14. Arstila, T. P., A. Casrouge, V. Baron, J. Even, J. Kanellopoulos, and P. Kourilsky. 1999. A direct estimate of the human αβ T cell receptor diversity. Science 286: 958-961.
15. Mason, D. 1998. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19: 395-404.
16. Rotzschke, O., K. Falk, S. Faath, and H. G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174: 1059-1071.
17. Agrewala, J. N., S. Deacock, S. Jurcevic, and R. Wilkinson. 1997. Peptide recognition by T-cell clones of an HLA-DRB1*1501/*0901 heterozygous donor is promiscuous only between parental alleles. Hum. Immunol. 55: 34-38.
18. Doherty, D. G., J. E. Penzotti, D. M. Koelle, W. W. Kwok, T. P. Lybrand, S. Masewicz, and G. T. Nepom. 1998. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J. Immunol. 161: 3527-3535.
19. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19: 2237-2242.
20. Brock, R., K. H. Wiesmuller, G. Jung, and P. Walden. 1996. Molecular basis for the recognition of two structurally different major histocompatibility complex/ peptide complexes by a single T-cell receptor. Proc. Natl. Acad. Sci USA 93: 13108-13113.
21. Basu, D., S. Horvath, I. Matsumoto, D. H. Fremont, and P. M. Allen. 2000. Molecular basis for recognition of an arthritic peptide and a foreign epitope on distinct MHC molecules by a single TCR. J. Immunol. 164: 5788-5796.
22. Hennecke, J., and D. C. Wiley. 2002. Structure of a complex of the human α/β T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195: 571-581.
23. Texier, C., S. Pouvelle, M. Busson, M. Herve, D. Charron, A. Menez, and B. Maillere. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164: 3177-3184.
24. Texier, C., S. Pouvelle-Moratille, M. Busson, D. Charron, A. Menez, and B. Maillere. 2001. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31: 1837-1846.
25. + T cells. Cancer Res. 60: 4946-4952.
26. Stockert, E., E. Jager, Y. T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187: 1349-1354.
27. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethe, P. Romero, T. Boon, and J. C. Renauld. 1996. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J. Invest. Dermatol. 107: 63-67.
28. Genevee, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22: 1261-1269.
29. + T cell responses against TRAG-3 in patients with melanoma and breast cancers. J. Immunol. 177: 2717-2727.
30. Benoist, C., and D. Mathis. 2001. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2: 797-801.
31. Goldrath, A. W., and M. J. Bevan. 1999. Selecting and maintaining a diverse T-cell repertoire. Nature 402: 255-262.
32. Hemmer, B., B. T. Fleckenstein, M. Vergelli, G. Jung, H. McFarland, R. Martin, and K. H. Wiesmuller. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185: 1651-1659.
33. Wucherpfennig, K. W., and J. L. Strominger. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80: 695-705.
34. Brehm, M. A., A. K. Pinto, K. A. Daniels, J. P. Schneck, R. M. Welsh, and L. K. Selin. 2002. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat. Immunol. 3: 627-634.
35. + memory T cells by viral variants. J. Exp. Med. 190: 1319-1328.
36. + T cell response. J. Exp. Med. 201: 1555-1565.
37. Cibotti, R., J. M. Kanellopoulos, J. P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Kourilsky. 1992. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89: 416-420.
38. + T cells are activated by "cross- dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol. 176: 1447-1455.
39. Gajewski, T. F. 2006. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 12: 2326s-2330s.
40. Loftus, D. J., C. Castelli, T. M. Clay, P. Squarcina, F. M. Marincola, M. I. Nishimura, G. Parmiani, E. Appella, and L. Rivoltini. 1996. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184: 647-657.
41. Sospedra, M., P. A. Muraro, I. Stefanova, Y. Zhao, K. Chung, Y. Li, M. Giulianotti, R. Simon, R. Mariuzza, C. Pinilla, and R. Martin. 2006. Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J. Immunol. 176: 1951-1961.
42. Reiser, J. B., C. Darnault, C. Gregoire, T. Mosser, G. Mazza, A. Kearney, P. A. van der Merwe, J. C. Fontecilla-Camps, D. Housset, and B. Malissen. 2003. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat. Immunol. 4: 241-247.